Eric Leblanc

1.7k total citations
38 papers, 1.4k citations indexed

About

Eric Leblanc is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Molecular Biology. According to data from OpenAlex, Eric Leblanc has authored 38 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 21 papers in Genetics and 16 papers in Molecular Biology. Recurrent topics in Eric Leblanc's work include Prostate Cancer Treatment and Research (27 papers), Estrogen and related hormone effects (21 papers) and Hormonal and reproductive studies (9 papers). Eric Leblanc is often cited by papers focused on Prostate Cancer Treatment and Research (27 papers), Estrogen and related hormone effects (21 papers) and Hormonal and reproductive studies (9 papers). Eric Leblanc collaborates with scholars based in Canada, United States and France. Eric Leblanc's co-authors include Artem Cherkasov, Paul S. Rennie, Fuqiang Ban, Kush Dalal, Kriti Singh, Nada Lallous, Kate Frewin, Nathan A. Lack, Huifang Li and Peter Axerio-Cilies and has published in prestigious journals such as Journal of Biological Chemistry, Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Eric Leblanc

37 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Leblanc Canada 21 684 679 433 324 307 38 1.4k
Eva Estébanez‐Perpiñá Spain 23 971 1.4× 455 0.7× 669 1.5× 149 0.5× 485 1.6× 40 1.7k
Kevin Kish United States 20 930 1.4× 240 0.4× 305 0.7× 209 0.6× 384 1.3× 38 2.0k
Nada Lallous Canada 19 558 0.8× 473 0.7× 203 0.5× 84 0.3× 149 0.5× 40 959
Tadas S. Vasaitis United States 19 525 0.8× 445 0.7× 384 0.9× 68 0.2× 307 1.0× 21 1.1k
Susan E. Kiefer United States 14 622 0.9× 182 0.3× 226 0.5× 114 0.4× 200 0.7× 21 1.4k
S. Elaine Barrie United Kingdom 16 564 0.8× 564 0.8× 265 0.6× 48 0.1× 362 1.2× 25 1.3k
Lalji K. Gediya United States 19 773 1.1× 338 0.5× 271 0.6× 64 0.2× 195 0.6× 26 1.3k
Takahito Hara Japan 24 757 1.1× 819 1.2× 347 0.8× 39 0.1× 456 1.5× 51 1.7k
Mark Salvati United States 15 399 0.6× 403 0.6× 357 0.8× 35 0.1× 359 1.2× 48 1.0k
Michael L. Mohler United States 19 419 0.6× 295 0.4× 269 0.6× 45 0.1× 416 1.4× 31 1.1k

Countries citing papers authored by Eric Leblanc

Since Specialization
Citations

This map shows the geographic impact of Eric Leblanc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Leblanc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Leblanc more than expected).

Fields of papers citing papers by Eric Leblanc

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Leblanc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Leblanc. The network helps show where Eric Leblanc may publish in the future.

Co-authorship network of co-authors of Eric Leblanc

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Leblanc. A scholar is included among the top collaborators of Eric Leblanc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Leblanc. Eric Leblanc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morin, Hélène, Mohit Pandey, Fuqiang Ban, et al.. (2023). Novel Inhibitors of androgen receptor's DNA binding domain identified using an ultra‐large virtual screening. Molecular Informatics. 42(8-9). e2300026–e2300026. 7 indexed citations
2.
Lallous, Nada, C. Antonio Sánchez, Bei Sun, et al.. (2021). Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients. Cancers. 13(12). 2939–2939. 19 indexed citations
3.
Ban, Fuqiang, Fan Zhang, Eric Leblanc, et al.. (2021). Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor. International Journal of Molecular Sciences. 22(5). 2493–2493. 22 indexed citations
4.
Gentile, Francesco, Michael Fernández, Fuqiang Ban, et al.. (2021). Automated discovery of noncovalent inhibitors of SARS-CoV-2 main protease by consensus Deep Docking of 40 billion small molecules. Chemical Science. 12(48). 15960–15974. 46 indexed citations
5.
Leblanc, Eric, Nada Lallous, Hélène Morin, et al.. (2019). Computer-Aided Discovery of Small Molecules Targeting the RNA Splicing Activity of hnRNP A1 in Castration-Resistant Prostate Cancer. Molecules. 24(4). 763–763. 34 indexed citations
6.
Fernández, Michael, Fuqiang Ban, Michael Hsing, et al.. (2018). Toxic Colors: The Use of Deep Learning for Predicting Toxicity of Compounds Merely from Their Graphic Images. Journal of Chemical Information and Modeling. 58(8). 1533–1543. 93 indexed citations
7.
Dalal, Kush, Hélène Morin, Fuqiang Ban, et al.. (2018). Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor. European Journal of Medicinal Chemistry. 157. 1164–1173. 14 indexed citations
8.
Lallous, Nada, Eric Leblanc, Fuqiang Ban, et al.. (2018). Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. European Journal of Medicinal Chemistry. 160. 108–119. 38 indexed citations
9.
Dalal, Kush, Fuqiang Ban, Huifang Li, et al.. (2018). Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer. Cancer Letters. 437. 35–43. 45 indexed citations
10.
Dalal, Kush, Meixia Che, Aishwariya Sharma, et al.. (2017). Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor–Chromatin Interactions. Molecular Cancer Therapeutics. 16(10). 2281–2291. 27 indexed citations
11.
Ban, Fuqiang, Kush Dalal, Huifang Li, et al.. (2017). Best Practices of Computer-Aided Drug Discovery: Lessons Learned from the Development of a Preclinical Candidate for Prostate Cancer with a New Mechanism of Action. Journal of Chemical Information and Modeling. 57(5). 1018–1028. 83 indexed citations
12.
Lallous, Nada, Stanislav Volik, Shannon Awrey, et al.. (2016). Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome biology. 17(1). 10–10. 154 indexed citations
13.
Lallous, Nada, Eric Leblanc, Mohamed D.H. Hassona, et al.. (2016). Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation. Molecular Cancer Therapeutics. 15(12). 2936–2945. 25 indexed citations
14.
Dalal, Kush, Mani Roshan‐Moniri, Aishwariya Sharma, et al.. (2015). Abstract 1778: Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. Cancer Research. 75(15_Supplement). 1778–1778. 1 indexed citations
15.
Hassona, Mohamed D.H., Eric Leblanc, Kate Frewin, et al.. (2014). Identification of a Potent Antiandrogen that Targets the BF3 Site of the Androgen Receptor and Inhibits Enzalutamide-Resistant Prostate Cancer. Chemistry & Biology. 21(11). 1476–1485. 59 indexed citations
16.
Ban, Fuqiang, Eric Leblanc, Huifang Li, et al.. (2014). Discovery of 1H-Indole-2-carboxamides as Novel Inhibitors of the Androgen Receptor Binding Function 3 (BF3). Journal of Medicinal Chemistry. 57(15). 6867–6872. 50 indexed citations
17.
Dalal, Kush, Mani Roshan‐Moniri, Aishwariya Sharma, et al.. (2014). Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.. Journal of Biological Chemistry. 289(49). 33877–33877. 6 indexed citations
18.
Li, Huifang, Mohamed D.H. Hassona, Nathan A. Lack, et al.. (2013). Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer. Molecular Cancer Therapeutics. 12(11). 2425–2435. 24 indexed citations
19.
20.
Cheng, Helen, Eric Leblanc, & Paul S. Rennie. (2011). In Vitro and In Vivo Silencing of the Androgen Receptor. Methods in molecular biology. 776. 95–112.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eva Estébanez‐Perpiñá Breakdown of academic impact, for papers by Kevin Kish Breakdown of academic impact, for papers by Nada Lallous Breakdown of academic impact, for papers by Tadas S. Vasaitis Breakdown of academic impact, for papers by Susan E. Kiefer Breakdown of academic impact, for papers by S. Elaine Barrie Breakdown of academic impact, for papers by Lalji K. Gediya Breakdown of academic impact, for papers by Takahito Hara Breakdown of academic impact, for papers by Mark Salvati Breakdown of academic impact, for papers by Michael L. Mohler
Rankless by CCL
2026